{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:12:29Z","timestamp":1781151149213,"version":"3.54.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07 trial evaluated a fixed-duration (15-month) immunochemotherapy approach in which after obinutuzumab-ibrutinib induction for 9\u00a0months, patients (n\u00a0= 10) in complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) &amp;lt;0.01% continued only ibrutinib 420\u00a0mg\/day for 6 additional months (I arm), whereas the majority (n\u00a0= 115) received up to 4 cycles of fludarabine\/cyclophosphamide-obinutuzumab 1000\u00a0mg alongside the ibrutinib (I-FCG arm). Primary analysis at month 16 showed that 84 of 135 (62.2%) patients enrolled achieved CR with a BM MRD &amp;lt;0.01%. Here, we report follow-up at median 63\u00a0months. Peripheral blood (PB) MRD was assessed 6\u00a0monthly beyond the end of treatment using a highly sensitive (10-6) flow cytometry technique. In the I-FCG arm, the PB MRD &amp;lt;0.01% rate (low-level positive &amp;lt;0.01% or undetectable with limit of detection \u226410-4) in evaluable patients was still 92.5% (74\/80) at month 40 and 80.6% (50\/62) at month 64. No differences in the PB MRD status were apparent per to the IGHV mutational status. In the overall population, 4-year progression-free and overall survival rates were 95.5% and 96.2%, respectively. Twelve deaths occurred overall. Fourteen serious adverse events occurred beyond the end of treatment. Thus, our fixed-duration immunochemotherapy approach produced deep and sustained PB MRD responses, high survival rates, and low long-term toxicity. A randomized trial is needed to compare our immunochemotherapy approach with a chemotherapy-free strategy. This trial was registered at www.clinicaltrials.gov as #NCT02666898.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009594","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T13:41:57Z","timestamp":1680874917000},"page":"3936-3945","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial"],"prefix":"10.1182","volume":"7","author":[{"given":"Anne-Sophie","family":"Michallet","sequence":"first","affiliation":[{"name":"1Department of Hematology, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-2656","authenticated-orcid":false,"given":"R\u00e9mi","family":"Letestu","sequence":"additional","affiliation":[{"name":"2Hematology Laboratory, Avicenne Hospital, H\u00f4pitaux universitaires Paris Seine Saint-Denis (HUPSSD), Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3240","authenticated-orcid":false,"given":"Magali","family":"Le Garff-Tavernier","sequence":"additional","affiliation":[{"name":"3Department of Hematology Biology, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-4476","authenticated-orcid":false,"given":"Lydia","family":"Campos","sequence":"additional","affiliation":[{"name":"4Department of Hematology Biology, Le Centre Hospitalier Universitaire (CHU) Saint Etienne, Saint Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ticchioni","sequence":"additional","affiliation":[{"name":"5Department of Immunology, CHU Nice, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Sarah","family":"Dilhuydy","sequence":"additional","affiliation":[{"name":"6Department of Hematology, CHU Bordeaux, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7747-113X","authenticated-orcid":false,"given":"Stephane","family":"Morisset","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Rouille","sequence":"additional","affiliation":[{"name":"7Department of Hematology, CHU Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Mah\u00e9","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Nantes University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"9Department of Hematology, CH Le Mans, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-6463","authenticated-orcid":false,"given":"Bruno","family":"Villemagne","sequence":"additional","affiliation":[{"name":"10Department of Hematology, CHD Vend\u00e9e, La Roche-sur-Yon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Ferrant","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Oncology, CH Lyon-Sud, Hospices Civils de Lyon, Universit\u00e9 Claude Bernard, Pierre-Benite, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-621X","authenticated-orcid":false,"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Cellular Therapy, CHU Hotel Dieu H\u00e9matologie, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1430-2574","authenticated-orcid":false,"given":"Alain","family":"Delmer","sequence":"additional","affiliation":[{"name":"13Department of Hematology, CHU Reims, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysiane","family":"Molina","sequence":"additional","affiliation":[{"name":"14Department of Hematology, CHU Grenoble, La Tronche, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[{"name":"15Department of Hematology, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tomowiak","sequence":"additional","affiliation":[{"name":"16Department of Hematology, CHU Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"de Guibert","sequence":"additional","affiliation":[{"name":"17Department of Hematology, CHU Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Orsini-Piocelle","sequence":"additional","affiliation":[{"name":"18Hematology Service, CH Annecy, Annecy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Banos","sequence":"additional","affiliation":[{"name":"19Department of Hematology, CH C\u00f4te Basque, Bayonne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Carassou","sequence":"additional","affiliation":[{"name":"20Department of Hematology, CH Metz, Metz, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"7Department of Hematology, CHU Montpellier, Montpellier, France"},{"name":"21Department of Hematology, Montpellier University Hospital, Montpelllier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc Mathieu","family":"Fornecker","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Strasbourg University Hospital, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"23Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dartigeas","sequence":"additional","affiliation":[{"name":"24Department of Hematology, CHU Tours, H\u00f4pital Bretonneau, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Truchan-Graczyk","sequence":"additional","affiliation":[{"name":"25Department of Hematology, CHU Angers, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Vilque","sequence":"additional","affiliation":[{"name":"26Institut d'H\u00e9matologie de Basse-Normandie, Centre Fran\u00e7ois Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se Aurran","family":"Schleinitz","sequence":"additional","affiliation":[{"name":"27Department of Hematology, Institut Paoli Calmettes, Marseille, Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cymbalista","sequence":"additional","affiliation":[{"name":"28Department of Hematology, Avicenne Hospital, HUPSSD, AP-HP, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lepr\u00eatre","sequence":"additional","affiliation":[{"name":"29Inserm U1245 and Department of Hematology, Centre Centre Henri-Becquerel and Normandie University UNIROUEN, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"L\u00e9vy","sequence":"additional","affiliation":[{"name":"30Department of Clinical Research, Avicenne Hospital, HUPSSD, AP-HP, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-6668","authenticated-orcid":false,"given":"Florence","family":"Nguyen-Khac","sequence":"additional","affiliation":[{"name":"15Department of Hematology, AP-HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"31Department of Hematology, Centre Hospitalier R\u00e9gional Universitaire de Nancy, H\u00f4pitaux de Brabois, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"4","key":"2023080716350566500_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.clml.2021.09.012","article-title":"SOHO state of the art updates and next questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds","volume":"22","author":"Thompson","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2023080716350566500_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hon.2583","article-title":"How to approach CLL in clinical practice","volume":"37","author":"Hallek","year":"2019","journal-title":"Hematol Oncol"},{"issue":"1","key":"2023080716350566500_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"2023080716350566500_bib4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3324\/haematol.2017.186387","article-title":"Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed\/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study","volume":"103","author":"Leblond","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"2023080716350566500_bib5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/s41375-018-0146-5","article-title":"Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study","volume":"32","author":"Stilgenbauer","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"2023080716350566500_bib6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9747","key":"2023080716350566500_bib7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"2023080716350566500_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023080716350566500_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2023080716350566500_bib10","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphcytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023080716350566500_bib11","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2023080716350566500_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023080716350566500_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2023080716350566500_bib14","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2023080716350566500_bib15","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"2023080716350566500_bib16","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"2023080716350566500_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2023080716350566500_bib18","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"34","key":"2023080716350566500_bib19","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase 2 CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023080716350566500_bib20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","article-title":"Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Cramer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023080716350566500_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"2023080716350566500_bib22","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2023080716350566500_bib23","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023080716350566500_bib24","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-021-01342-x","article-title":"Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: alliance A041202","volume":"35","author":"Ruppert","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2023080716350566500_bib25","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"2023080716350566500_bib26","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib induction","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2023080716350566500_bib27","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arryhthmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"2023080716350566500_bib28","doi-asserted-by":"crossref","first-page":"720704","DOI":"10.3389\/fonc.2021.720704","article-title":"Monitoring and managing BTK inhibitor treatment-related adverse events in clincial practice","volume":"11","author":"O\u2019Brien","year":"2021","journal-title":"Front Oncol"},{"issue":"22","key":"2023080716350566500_bib29","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2023080716350566500_bib30","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023080716350566500_bib31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia. A nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"23","key":"2023080716350566500_bib32","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023080716350566500_bib33","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"36","key":"2023080716350566500_bib34","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023080716350566500_bib35","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2352-3026(19)30113-9","article-title":"Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial","volume":"6","author":"Michallet","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"2023080716350566500_bib36","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood.2020008164","article-title":"A\u00a0fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial","volume":"137","author":"Michallet","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023080716350566500_bib37","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","article-title":"Ibrutinib plus fludarabine, cyclophosphamide, and ritixuimab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"issue":"12","key":"2023080716350566500_bib38","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1038\/s41375-021-01280-8","article-title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations","volume":"35","author":"Jain","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"2023080716350566500_bib39","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2023080716350566500_bib40","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41375-020-01009-z","article-title":"Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia","volume":"35","author":"Letestu","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2023080716350566500_bib41","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2023080716350566500_bib42","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2021-146624","article-title":"Longer term follow-up of a multicenter, phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, rituximab (iFCR) as initial therapy for younger patients with chronic lymphocytic leukemia","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"key":"2023080716350566500_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/01.HS9.0000843488.43813.af","article-title":"Long term outcomes of iFCG regimen for firstline treatment of patients with CLL with mutated IGHV and without del(17p)\/TP53 mutation [abstract]","volume":"6","author":"Jain","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2023080716350566500_bib44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2021-152319","article-title":"Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial","volume":"138","author":"Hillmen","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023080716350566500_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood-2022-160338","article-title":"Treatment outcomes after undetectable MRD with first-line ibrutinib (Ibr) plus venetoclax (Ven): fixed duration treatment (placebo) versus continued Ibr with up to 5 years median follow-up in the CAPTIVATE study","volume":"140","author":"Allan","year":"2022","journal-title":"Blood"},{"key":"2023080716350566500_bib46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/01.HS9.0000845560.07338.2d","article-title":"Fixed-duration (FD) ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 3-year follow-up from the phase 2 CAPTIVATE study FD cohort [abstract]","volume":"6","author":"Moreno","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2023080716350566500_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2021-146161","article-title":"A\u00a0randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR\/BR) in frontline chronic lymphocytic leukemia of fit patients: first co-primary endpoint analysis of the International Intergroup GAIA (CLL13) trial","volume":"138","author":"Eichhorst","year":"2021","journal-title":"Blood"},{"key":"2023080716350566500_bib48","article-title":"Time-limited venetoclax-obinutuzumab +\/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA\/CLL13 trial [abstract]","author":"Eichhorst","year":"2022","journal-title":"EHA2022"},{"key":"2023080716350566500_bib49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.HS9.0000843472.57904.29","article-title":"The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial [abstract]","volume":"6","author":"Hillmen","year":"2022","journal-title":"HemaSphere"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3936\/2069839\/blooda_adv-2022-009594-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3936\/2069839\/blooda_adv-2022-009594-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T16:35:38Z","timestamp":1691426138000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/15\/3936\/495264\/A-fixed-duration-immunochemotherapy-approach-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009594","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}